Skip to main content
Top
Published in: Clinical Research in Cardiology 8/2010

01-08-2010 | Original Paper

Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: prevalence and co-prevalence

Authors: Jan Börgel, Stephanie Springer, Jasmin Ghafoor, Daniel Arndt, Hans-Werner Duchna, Andreas Barthel, Sibylle Werner, Josef Van Helden, Christoph Hanefeld, Horst Neubauer, Daniel Bulut, Andreas Mügge

Published in: Clinical Research in Cardiology | Issue 8/2010

Login to get access

Abstract

Background

Hypertensive urgency/emergency occurs frequently, yet no prospective data on common secondary causes, including sleep apnea (SA), renal artery stenosis (RAS), and hyperaldosteronism, are available.

Methods

Patients presenting to the emergency room for over 1 year with systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥100 mmHg and typical symptoms were included. RAS was diagnosed by direct duplex/Doppler ultrasound of the renal artery, resistance index, and imaging. The aldosterone/renin ratio (ARR) was determined from morning blood samples taken with the patients supine after ≥2 h of rest. A positive ARR (>50) was followed by saline infusion to exclude primary hyperaldosteronism. SA was evaluated by nasal breathing flow screening; when positive [apnea/hypopnea index (AHI) >5/h], complete polysomnography was performed.

Results

Of 161 patients (age, 66.0 ± 13.1 years; BMI, 28.6 ± 5.1 kg), 131 had previously identified hypertension (duration, 12.7 ± 11.5 years; 1.9 ± 1.5 antihypertensive medications). SA was found in 114 (70.8%) patients [18% mild (AHI: 5–15/h), 26.8% moderate (15.1–30/h), and 24.2% severe (>30/h)]. Aldosterone levels exceeded 160 pg/ml in 22 of 23 patients with hyperaldosteronism; 4 had primary and 12 had secondary hyperaldosteronism. Thirteen (8.1%) patients had RAS. Three secondary causes were found in 1 patient (0.6%), ≥2 in 25 (15.5%), and ≥1 in 124 patients (77.0%). Of 150 detected secondary causes, only 5 were recognized previously.

Conclusions

Secondary causes of hypertension are common and predominantly unrecognized in patients with hypertensive urgency/emergency. Co-prevalence of secondary causes occurs in about 15% and should be considered before therapeutic intervention.
Literature
1.
go back to reference Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P (1996) Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension 27(1):144–147PubMed Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P (1996) Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension 27(1):144–147PubMed
2.
go back to reference (1997) Practice parameters for the indications for polysomnography and related procedures. Polysomnography Task Force, American Sleep Disorders Association Standards of Practice Committee. Sleep 20(6):406–422 (1997) Practice parameters for the indications for polysomnography and related procedures. Polysomnography Task Force, American Sleep Disorders Association Standards of Practice Committee. Sleep 20(6):406–422
3.
go back to reference Zeller T, Bonvini RF, Sixt S (2008) Color-coded duplex ultrasound for diagnosis of renal artery stenosis and as follow-up examination after revascularization. Catheter Cardiovasc Interv 71(7):995–999CrossRefPubMed Zeller T, Bonvini RF, Sixt S (2008) Color-coded duplex ultrasound for diagnosis of renal artery stenosis and as follow-up examination after revascularization. Catheter Cardiovasc Interv 71(7):995–999CrossRefPubMed
4.
go back to reference Seiler L, Rump LC, Schulte-Monting J et al (2004) Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 150(3):329–337CrossRefPubMed Seiler L, Rump LC, Schulte-Monting J et al (2004) Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 150(3):329–337CrossRefPubMed
5.
go back to reference Calhoun DA, Jones D, Textor S et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117(25):e510–e526CrossRefPubMed Calhoun DA, Jones D, Textor S et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117(25):e510–e526CrossRefPubMed
6.
go back to reference (1967) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202(11):1028–1034 (1967) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202(11):1028–1034
7.
go back to reference Krijnen P, van Jaarsveld BC, Deinum J, Steyerberg EW, Habbema JD (2004) Which patients with hypertension and atherosclerotic renal artery stenosis benefit from immediate intervention? J Hum Hypertens 18(2):91–96CrossRefPubMed Krijnen P, van Jaarsveld BC, Deinum J, Steyerberg EW, Habbema JD (2004) Which patients with hypertension and atherosclerotic renal artery stenosis benefit from immediate intervention? J Hum Hypertens 18(2):91–96CrossRefPubMed
8.
go back to reference van Jaarsveld BC, Krijnen P, Pieterman H et al (2000) The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 342(14):1007–1014CrossRefPubMed van Jaarsveld BC, Krijnen P, Pieterman H et al (2000) The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 342(14):1007–1014CrossRefPubMed
9.
go back to reference Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA (2007) Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131(2):453–459CrossRefPubMed Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA (2007) Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131(2):453–459CrossRefPubMed
10.
go back to reference Calhoun DA, Nishizaka MK, Zaman MA, Harding SM (2004) Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125(1):112–117CrossRefPubMed Calhoun DA, Nishizaka MK, Zaman MA, Harding SM (2004) Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125(1):112–117CrossRefPubMed
11.
go back to reference Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP (2004) Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22(11):2217–2226CrossRefPubMed Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP (2004) Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22(11):2217–2226CrossRefPubMed
12.
go back to reference Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40(6):892–896CrossRefPubMed Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40(6):892–896CrossRefPubMed
13.
go back to reference Anderson GH Jr, Blakeman N, Streeten DH (1994) The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12(5):609–615CrossRefPubMed Anderson GH Jr, Blakeman N, Streeten DH (1994) The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12(5):609–615CrossRefPubMed
14.
go back to reference Logan AG, Perlikowski SM, Mente A et al (2001) High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 19(12):2271–2277CrossRefPubMed Logan AG, Perlikowski SM, Mente A et al (2001) High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 19(12):2271–2277CrossRefPubMed
15.
go back to reference Nieto FJ, Young TB, Lind BK et al (2000) Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 283(14):1829–1836CrossRefPubMed Nieto FJ, Young TB, Lind BK et al (2000) Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 283(14):1829–1836CrossRefPubMed
16.
go back to reference Peppard PE, Young T, Palta M, Skatrud J (2000) Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342(19):1378–1384CrossRefPubMed Peppard PE, Young T, Palta M, Skatrud J (2000) Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342(19):1378–1384CrossRefPubMed
17.
go back to reference Grote L, Hedner J, Peter JH (2000) Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens 18(6):679–685CrossRefPubMed Grote L, Hedner J, Peter JH (2000) Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens 18(6):679–685CrossRefPubMed
18.
go back to reference Somers VK, Dyken ME, Clary MP, Abboud FM (1995) Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96(4):1897–1904CrossRefPubMed Somers VK, Dyken ME, Clary MP, Abboud FM (1995) Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96(4):1897–1904CrossRefPubMed
19.
go back to reference Oldenburg O, Lamp B, Freivogel K, Bitter T, Langer C, Horstkotte D (2008) Low night-to-night variability of sleep disordered breathing in patients with stable congestive heart failure. Clin Res Cardiol 97(11):836–842CrossRefPubMed Oldenburg O, Lamp B, Freivogel K, Bitter T, Langer C, Horstkotte D (2008) Low night-to-night variability of sleep disordered breathing in patients with stable congestive heart failure. Clin Res Cardiol 97(11):836–842CrossRefPubMed
20.
go back to reference Becker HF, Jerrentrup A, Ploch T et al (2003) Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107(1):68–73CrossRefPubMed Becker HF, Jerrentrup A, Ploch T et al (2003) Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107(1):68–73CrossRefPubMed
21.
go back to reference Sanner BM, Tepel M, Markmann A, Zidek W (2002) Effect of continuous positive airway pressure therapy on 24-hour blood pressure in patients with obstructive sleep apnea syndrome. Am J Hypertens 15(3):251–257CrossRefPubMed Sanner BM, Tepel M, Markmann A, Zidek W (2002) Effect of continuous positive airway pressure therapy on 24-hour blood pressure in patients with obstructive sleep apnea syndrome. Am J Hypertens 15(3):251–257CrossRefPubMed
22.
go back to reference Logan AG, Tkacova R, Perlikowski SM et al (2003) Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J 21(2):241–247CrossRefPubMed Logan AG, Tkacova R, Perlikowski SM et al (2003) Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J 21(2):241–247CrossRefPubMed
23.
go back to reference Borgel J, Sanner BM, Keskin F et al (2004) Obstructive sleep apnea and blood pressure. Interaction between the blood pressure-lowering effects of positive airway pressure therapy and antihypertensive drugs. Am J Hypertens 17(12 Pt 1):1081–1087CrossRefPubMed Borgel J, Sanner BM, Keskin F et al (2004) Obstructive sleep apnea and blood pressure. Interaction between the blood pressure-lowering effects of positive airway pressure therapy and antihypertensive drugs. Am J Hypertens 17(12 Pt 1):1081–1087CrossRefPubMed
24.
go back to reference Marin JM, Carrizo SJ, Vicente E, Agusti AG (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464):1046–1053PubMed Marin JM, Carrizo SJ, Vicente E, Agusti AG (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464):1046–1053PubMed
25.
go back to reference Buchner NJ, Sanner BM, Borgel J, Rump LC (2007) Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 176(12):1274–1280CrossRefPubMed Buchner NJ, Sanner BM, Borgel J, Rump LC (2007) Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 176(12):1274–1280CrossRefPubMed
26.
go back to reference Gotsopoulos H, Kelly JJ, Cistulli PA (2004) Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 27(5):934–941PubMed Gotsopoulos H, Kelly JJ, Cistulli PA (2004) Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 27(5):934–941PubMed
27.
go back to reference Otsuka R, Ribeiro de Almeida F, Lowe AA, Linden W, Ryan F (2006) The effect of oral appliance therapy on blood pressure in patients with obstructive sleep apnea. Sleep Breath 10(1):29–36CrossRefPubMed Otsuka R, Ribeiro de Almeida F, Lowe AA, Linden W, Ryan F (2006) The effect of oral appliance therapy on blood pressure in patients with obstructive sleep apnea. Sleep Breath 10(1):29–36CrossRefPubMed
28.
go back to reference Mosso L, Carvajal C, Gonzalez A et al (2003) Primary aldosteronism and hypertensive disease. Hypertension 42(2):161–165CrossRefPubMed Mosso L, Carvajal C, Gonzalez A et al (2003) Primary aldosteronism and hypertensive disease. Hypertension 42(2):161–165CrossRefPubMed
29.
go back to reference Douma S, Petidis K, Doumas M et al (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371(9628):1921–1926CrossRefPubMed Douma S, Petidis K, Doumas M et al (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371(9628):1921–1926CrossRefPubMed
30.
go back to reference Rossi GP, Bernini G, Caliumi C et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48(11):2293–2300CrossRefPubMed Rossi GP, Bernini G, Caliumi C et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48(11):2293–2300CrossRefPubMed
31.
go back to reference Zeller T, Frank U, Spath M, Roskamm H (2001) Color duplex ultrasound imaging of renal arteries and detection of hemodynamically relevant renal artery stenoses. Ultraschall Med 22(3):116–121CrossRefPubMed Zeller T, Frank U, Spath M, Roskamm H (2001) Color duplex ultrasound imaging of renal arteries and detection of hemodynamically relevant renal artery stenoses. Ultraschall Med 22(3):116–121CrossRefPubMed
32.
go back to reference Krumme B, Blum U, Schwertfeger E et al (1996) Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. Kidney Int 50(4):1288–1292CrossRefPubMed Krumme B, Blum U, Schwertfeger E et al (1996) Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. Kidney Int 50(4):1288–1292CrossRefPubMed
Metadata
Title
Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: prevalence and co-prevalence
Authors
Jan Börgel
Stephanie Springer
Jasmin Ghafoor
Daniel Arndt
Hans-Werner Duchna
Andreas Barthel
Sibylle Werner
Josef Van Helden
Christoph Hanefeld
Horst Neubauer
Daniel Bulut
Andreas Mügge
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Clinical Research in Cardiology / Issue 8/2010
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0148-4

Other articles of this Issue 8/2010

Clinical Research in Cardiology 8/2010 Go to the issue

Letter to the Editor

Galectin 3 in heart failure